Navigation Links
New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes



AMADEO, a randomized, double-blind, forced-titration, parallel-group, multicentre study, included 860 hypertensive patients ((greater than)130/80mmHg) with type 2 diabetes and overt nephropathy from 124 centres in 10 countries. Patients were randomized to receive treatment with either telmisartan 80mg or losartan 100mg. To ensure blood pressure control in the two patient groups other non- ARB treatments (hydrochlorothiazide or calcium channel blocker) were added, if needed.

After one year's treatment, telmisartan was significantly more effective than losartan in reducing the amount of protein excreted in the urine. The primary end point of the study was reduced by 29% with telmisartan vs. 20% with losartan; p=0.0284(1). Telmisartan was superior to losartan on the primary endpoint, a change from baseline after 12 months (log transformed Urinary Protein creatinine ratio) of 0.71 (95% CI; 0.66, 0.77) vs. 0.80 (95% CI; 0.74,0.87) for losartan; p=0.0284.(1) No significant difference in blood pressure control or number of adverse events was observed between the two treatments groups(1). Proteinuria (high levels of protein in the urine) is a very important signal for disease severity in diabetic nephropathy and is also considered a relevant cardiovascular risk factor. Renal outcomes trials have shown that reductions of (greater than)30% at six months are strongly linked to slowed progression to end-stage kidney disease and reduced cardiovascular events.(6)

AMADEO successfully concludes the series of PROTECTION studies which are part of an extensive ongoing trial programme, including clinical and observational studies, investigating the outstanding effects of telmisartan compared with other treatments for hypertension, including other available ARBs. The trials established the effects of telmisartan in providing powerful blood pressure reductions from morning to morning as well as organ-protective
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:1/15/2014)... FRANKLIN, Ohio , Jan. 15, 2014  A novel wearable ... it easy and painless for patients to self-inject prescription drugs ... of disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic ... expected to grow to $220B by 2018, according to analysts.   ...
(Date:1/14/2014)... Healthcare Services, Inc. ("DHS"), a portfolio company of GMH Ventures ... Equipment, Inc. ("Progressive") of Clarion, PA ... not disclosed. Progressive is a full service ... sleep, mobility, and respiratory products to customers in the western ...
(Date:1/14/2014)... N.Y. , Jan. 14, 2014   Oligomerix, Inc. , ... modifying therapeutics for Alzheimer,s disease (AD) and related neurodegenerative ... to Valhalla, NY as of ... laboratory space at New York Medical College. ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... MEETING, Pa., Nov. 8, 2010 Keeping radiation ... hospitals, particularly in computed tomography (CT), which has undergone some ... side is that CT delivers some of the highest radiation ... measures for delivering the appropriate radiation dose can result in ...
... Biotechnologies Corporation, a leader in the emerging field of ... financial support for the company,s lead oncology product, Rexin-G, ... Services (HHS), and the National Institutes of Health (NIH) ... latest support for the clinical advancement of Rexin-G comes ...
Cached Medicine Technology:ECRI Institute Service to Address CT Radiation Dose Safety 2ECRI Institute Service to Address CT Radiation Dose Safety 3Epeius Biotechnologies Awarded Federal Grant Advancing Tumor-Targeted Cancer Therapy 2
(Date:4/24/2014)... me out to the ballgame, doesn,t exactly conjure up ... likely culprits include French fries, soda and the occasional ... play youth baseball, eating unhealthy food during practices and ... researchers at Wake Forest Baptist Medical Center. The study, ... Obesity , found that high-calorie snacks and sugar-sweetened drinks ...
(Date:4/24/2014)... the relevance of palliation in advanced cancer are ... trials (RCTs). This is the result of an ... Efficiency in Health Care (IQWiG), which has now ... external experts, IQWiG analysed studies on four solid ... and pancreatic cancer. For this purpose, the research ...
(Date:4/24/2014)... one of 30 grants from the National Cancer Institute ... in its new National Clinical Trials Network ... investigators charged with distributing resources in a more effective ... reflects recommendations from a 2010 Institute of Medicine ... Faster design, launch, and completion of clinical ...
(Date:4/23/2014)... pilot study by Massachusetts General Hospital (MGH) investigators may ... treatment for a serious medical problem use of ... caused by the Clostridium difficile ( C. ... online in the journal Clinical Infectious Diseases , ... material from donors unrelated to patients was as successful ...
(Date:4/23/2014)... M.D., scientific director at the National Institute of Arthritis ... the 2014 recipient of the Ross Prize in Molecular ... Molecular Medicine . The award will be given ... Sciences in Manhattan, followed by scientific presentations by Dr. ... the National Institutes of Health. , The award, which ...
Breaking Medicine News(10 mins):Health News:Take the bat, leave the candy 2Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 3Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2
... and dairy products, study finds, , FRIDAY, June 26 ... products can increase your risk for pancreatic cancer, researchers ... cancer, which is usually fatal, is the fourth-leading cause ... factors for developing the disease have been identified, including ...
... Calif., June 26 Discus Dental, LLC ("Discus") today announced ... court against Florida-based BSML, Inc. ("BSML") charging BSML with breach ... its lawsuit, Discus seeks to end a license agreement with ... order prohibiting BSML from future use of the trademark, and ...
... of Company Exemplifies the Best in Retirement Living , , ... housing will outpace supply in the coming years. Couple that trend with ... the senior housing industry looks very different than it did a decade ... Living, a national leader in senior living ...
... breach of contract , , DALLAS, June 26 A ... two years ago won again Thursday, when an appellate court affirmed ... Court of Appeals for the Fifth District of Texas at Dallas ... 2007 judgment against Pinnacle Anesthesia Consultants, P.A., which provides obstetric anesthesiology ...
... , NEW YORK, June 26 Selecciones , ... the American Heart Association,s (AHA) Go Red For ... retailers, for a second consecutive year in the multi-platform awareness program, ... to the threat of heart disease. , , To ...
... deadlier than a heart attack, experts say, with chances for ... star Michael Jackson probably did not die on Thursday of ... sudden cardiac arrest, experts say. , It,s not yet clear ... Angeles home, but that assumption has been made by many ...
Cached Medicine News:Health News:Eating Animal Fat May Lead to Pancreatic Cancer 2Health News:Eating Animal Fat May Lead to Pancreatic Cancer 3Health News:Discus Dental Files Suit to Protect BriteSmile(R) Trademark 2Health News:Aegis Living Was Created To Place People First in Senior and Assisted Living Communities 2Health News:Aegis Living Was Created To Place People First in Senior and Assisted Living Communities 3Health News:Appeals Court OKs Multimillion-Dollar Judgment for Dallas Doctor 2Health News:Photos: Selecciones, Reader's Digest, The American Heart Association's Go Red For Women and Macy's Reach Hispanic Women With Message of Heart Health 2Health News:Jackson's Death Puts Spotlight on Sudden Cardiac Arrest 2Health News:Jackson's Death Puts Spotlight on Sudden Cardiac Arrest 3
Open blade design with aspiration capabilities for removing fluids from the operative site. 19 gauge wire....
Designed to provide open approaches of the keratome to the cornea for either the left or right eye. Lightweight wire design adds to the comfort of the instrument when in place....
Solid 14 mm free-swinging blades, suture posts, and stabilizing disk. Dull finish....
Designed for use with foster enucleation snare (E3670). Package of 12 stainless steel wires. Overall length 5.3 inches....
Medicine Products: